The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

The SANRECO study investigates divesiran for polycythemia vera, focusing on regulating iron metabolism to control red blood cell production. Current PV treatments include therapeutic phlebotomy, ...

Protagonist Therapeutics, Inc. (PTGX) has been making great progress to advance the use of its drug rusfertide for the treatment of patients with polycythemia vera in the ongoing phase 3 study. Matter ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., March 02, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) today announced that the U.S. Food and ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule ...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep ...

CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

Uncontrolled PV is highlighted by a key opinion leader. Aaron Gerds, MD, MS: Patients who are older or have a history of thrombosis, really the mainstay of treatment in addition to a low-dose aspirin ...